SCHEMBL7677565

SCHEMBL7677565

CC(C)(C)OC(=O)NCCN1CCc2ccc(Br)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
NFKB1 P19838 1/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
HIF1A Q16665 1/20 0.48
LMNA P02545 1/20 0.47
PMP22 Q01453 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GFER P55789 1/20 0.47
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
DRD2 P14416 9/20 0.45
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
SIGMAR1 Q99720 2/20 0.39
FPR3 P25089 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8078377 0.87 DRD2 (0.46) CYP11B1CYP11B2DRD2HDAC1HDAC6
SCHEMBL7673879 0.86 DRD2 (0.53) HTR2AHTR2CHTR2BCYP11B1CYP11B2
SCHEMBL7673592 0.81 HTR2A (0.56) CYP1A2CYP3A4CYP2D6NFKB1HTR2A
SCHEMBL31129885 0.81 CYP11B1 (0.47) CYP11B1CYP11B2DRD2
SCHEMBL7673597 0.81 HTR2A (0.56) CYP1A2CYP3A4CYP2D6NFKB1HTR2A
SCHEMBL5212016 0.80 DRD2 (0.47) CYP11B1CYP11B2DRD2SIGMAR1
SCHEMBL21281416 0.79 MTNR1A (0.46) CYP11B1CYP11B2DRD2
SCHEMBL2145054 0.79 SMN1; SMN2 (0.41) CYP11B1CYP11B2DRD2HDAC1HDAC6
SCHEMBL15981289 0.77 CAMK2D (0.42) CYP11B1CYP11B2DRD2TRPV1FPR3
SCHEMBL5212333 0.77 DRD2 (0.49) DRD2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed